Key result
Antihypertensive drugs that inhibit the sympathetic nervous system may best reduce cardiovascular risk by attenuating sympathetic tone and its adverse metabolic and cardiovascular consequences.
Why the study?
Do antihypertensive drugs that inhibit the sympathetic nervous system best reduce cardiovascular risk in patients with essential hypertension?
Do antihypertensive drugs that inhibit the sympathetic nervous system best reduce cardiovascular risk in patients with essential hypertension?
The review highlights the adverse metabolic and cardiovascular consequences of sympathetic activation in hypertension, suggesting that sympatholytic antihypertensive drugs may offer optimal cardiovascular risk reduction.
May favor sympatholytics to curb sympathetic-driven risk in hypertension; leaves open prospective RCTs for confirmation.
Several studies have demonstrated that essential hypertension is accompanied by sympathetic activation, which contributes to blood pressure elevation. Sympathetic activation also has adverse consequences in hypertensive patients beyond initiating blood pressure elevation. There is evidence that neural vasoconstriction has metabolic effects in skeletal muscle, impairing glucose delivery to muscles. In the liver, retarding of post prandial clearance of lipids contributes to hyperlipidemia. Cardiac sympathetic activation is a probable cause of sudden death in hearth failure. A trophic effect of sympathetic activation on cardiovascular growth is also likely, contributing to the development of left ventricular hypertrophy. Consequently, one of the major aims of antihypertensive therapy should be to attenuate sympathetic tone.It is possible that, among the antihypertensive drugs available, those inhibiting the sympathetic nervous system might best reduce cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Rabbia et al. (2001) conducted a review in Essential hypertension. Antihypertensive drugs inhibiting the sympathetic nervous system was evaluated. Antihypertensive drugs that inhibit the sympathetic nervous system may best reduce cardiovascular risk by attenuating sympathetic tone and its adverse metabolic and cardiovascular consequences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: